Fairmount Healthcare Fund II L.P. 4

What Happened

• Fairmount Funds Management LLC (reported as a 10% owner) purchased 1,176,470 shares of Viridian Therapeutics, Inc. (VRDN) in an open-market/private purchase on 2026-05-11 at $17.00 per share, for a total of $19,999,990. This was a straight purchase (code P), which is a buy rather than a sale.

Key Details

• Transaction date and price: 2026-05-11 — 1,176,470 shares at $17.00 each.
• Total value: $19,999,990 (~$20.0M).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over securities held by Fairmount Healthcare Fund II LP (Fund II) and disclaim beneficial ownership of Fund II’s holdings except to the extent of any pecuniary interest.
• Remark: The reporting persons note that Tomas Kiselak (a Managing Member of Fairmount) serves on Viridian’s board, and the reporting persons "may each be deemed a director by deputization."
• Filing timeliness: Report covers period 2026-05-11 and was filed 2026-05-13 (filed within the standard 2-business-day window).

Context

• This is an institutional 10% owner purchase, not a routine executive sale; institutional buys can signal accumulation but do not by themselves prove intent.
• The filing’s footnote indicates the entity manages Fund II’s holdings and largely disclaims direct beneficial ownership of those fund-held shares for Rule 16 purposes.